Management of Myelofibrosis: from Diagnosis to New Target Therapies
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Management of Myelofibrosis: from Diagnosis to New Target Therapies
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 21, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-30
DOI
10.1007/s11864-020-00734-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
- (2020) John Mascarenhas et al. BLOOD
- Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
- (2019) Simon T. Durrant et al. HAEMATOLOGICA
- Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
- (2019) Alessandra Iurlo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib
- (2019) Aaron T. Gerds et al. LEUKEMIA RESEARCH
- INTEGRATING CLINICAL, MORPHOLOGICAL, AND MOLECULAR DATA TO ASSESS PROGNOSIS IN PATIENTS WITH PRIMARY MYELOFIBROSIS AT DIAGNOSIS: A PRACTICAL APPROACH
- (2019) Alessandra Iurlo et al. HEMATOLOGICAL ONCOLOGY
- A journey through infectious risk associated with ruxolitinib
- (2019) Emanuela Sant’Antonio et al. BRITISH JOURNAL OF HAEMATOLOGY
- Fedratinib: First Approval
- (2019) Hannah A. Blair DRUGS
- Impact of bone marrow fibrosis grade in post‐polycythemia vera and post‐essential thrombocythemia myelofibrosis: A study of the MYSEC group
- (2019) Barbara Mora et al. AMERICAN JOURNAL OF HEMATOLOGY
- Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients
- (2019) Claire N Harrison et al. BLOOD
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
- (2019) Elena Maria Elli et al. Frontiers in Oncology
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2019) J. Mascarenhas et al. LEUKEMIA RESEARCH
- Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
- (2018) Edit Porpaczy et al. BLOOD
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia
- (2018) Adolfo Enrique Diaz et al. Future Oncology
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
- (2018) Tiziano Barbui et al. LEUKEMIA
- Management of Myelofibrosis-Related Cytopenias
- (2018) Prithviraj Bose et al. Current Hematologic Malignancy Reports
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- Benefits and risks of JAK inhibition
- (2018) Luca Arcaini et al. BLOOD
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2017) John Mascarenhas et al. LEUKEMIA RESEARCH
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Development of TG101348 for the treatment of JAK2-driven malignancies
- (2017) J. Hood et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition
- (2016) Goro Sashida et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
- (2016) M Marchetti et al. LEUKEMIA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib
- (2015) Alessandra Iurlo et al. ANNALS OF HEMATOLOGY
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
- (2015) Adam J. Mead et al. BRITISH JOURNAL OF HAEMATOLOGY
- Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
- (2015) N M Kröger et al. LEUKEMIA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?
- (2014) Matteo Molica et al. ANNALS OF HEMATOLOGY
- Imatinib and ruxolitinib association: first experience in two patients
- (2014) A. Iurlo et al. HAEMATOLOGICA
- Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment
- (2014) Lana X. Tong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
- (2014) A Pardanani et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- The evolving genomic landscape of myeloproliferative neoplasms
- (2014) J. Nangalia et al. Hematology-American Society of Hematology Education Program
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
- (2013) Daniel J. DeAngelo et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Mutations and prognosis in primary myelofibrosis
- (2013) A M Vannucchi et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
- (2012) V. Gupta et al. BLOOD
- The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis
- (2012) Umberto Gianelli et al. MODERN PATHOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
- (2009) A Pardanani et al. LEUKEMIA
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now